NEOCINE
DEAD

Serial Number

98777335

Owner

NeoCine Therapeutics Inc.

Attorney

Theo Rieu

Filing Date

Sep 30, 2024

Add to watchlist:

No watchlists yet
View on USPTO

NEOCINE Trademark

Serial Number: 98777335

NEOCINE is a trademark filed by NeoCine Therapeutics Inc. on September 30, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

NeoCine Therapeutics Inc.

1521 Concord Pike, Suite 1201
Wilmington, DE 19803

Entity Type: 03

Trademark Details

Filing Date

September 30, 2024

Registration Date

Not Registered

Published for Opposition

May 13, 2025

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer; biological preparations for medical use in the treatment of cancer; immunotherapeutic pharmaceutical products and personalized vaccines designed to treat cancer by targeting specific neoepitopes that control tumors in vivo; anti-cancer drugs; therapeutic vaccines; diagnostic preparations for medical purposes, including those used to identify neoepitopes associated with tumor control

Medical analysis services for the treatment of cancer and the identification and analysis of neoepitopes that control tumors in vivo; medical services, namely, providing therapies for treating cancer; medical testing and medical diagnostic services for processing cancer and normal protein sets to identify high-quality patient-specific neoepitopes for personalized cancer vaccine development; preparation and dispensing of personalized immunotherapies and neoepitope-based cancer vaccines tailored to individual patient profiles

Downloadable computer software for the identification and analysis of neoepitopes that control tumors in vivo; downloadable computer software platforms for processing cancer and normal protein sets, identifying high-quality patient-specific neoepitopes, and designing personalized cancer vaccines; downloadable bioinformatics software for predicting the immunogenicity of neoepitopes and aiding in the design of targeted cancer therapies

Scientific research and development in the field of oncology, specifically focused on identifying and analyzing neoepitopes that control tumors in vivo for the development of personalized cancer vaccines; medical and scientific research related to the processing of cancer and normal protein sets, identification of high-quality patient-specific neoepitopes, and design of immunotherapeutic treatments; providing temporary use of non-downloadable software for the prediction of neoepitope immunogenicity and the design of targeted cancer vaccines

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 9, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 9, 2026 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 8, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 13, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 13, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 7, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 10, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 10, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 10, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 10, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 10, 2025 CNEA
ASSIGNED TO EXAMINER
Apr 4, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 3, 2025 NWOS
NEW APPLICATION ENTERED
Sep 30, 2024 NWAP